



האוניברסיטה העברית בירושלים
הפקולטה לחקלאות, מזון וסביבה ע"ש רוברט ה. סמית
המכון לביוכימיה, מדעי המזון והתזונה

Yaakov Bar-Tana, MD, PhD

Hebrew University Medical School

http://www.huji.ac.il/data/controller/ihoker/MOP-STAFF_LINK?sno=369743&Save_t=

Title:

אסטרטגיה טיפולית בסינדרום המטבולי

המפגש יתקיים

ביום א', 25 ינואר 2015, בשעה 9:00

מועדון סגל

(1/25/2015, 9:00, Faculty Club)

Abstract:

The Metabolic Syndrome (MetS) and Type 2 diabetes (T2D) comprise a cluster of diseases including obesity, hyperglycemia, hyperinsulinemia, combined dyslipidemia (increased plasma triglycerides, increased small-dense LDL, low HDL-cholesterol), and essential hypertension. MetS and T2D are epidemic in Western and Westernizing communities, and result in major health and financial load for inflicted individuals and communities. Currently marketed as well as pipeline drugs treat individual diseases of MetS/T2D, while falling short of offering an etiology-based comprehensive treatment mode. Hence, MetS/T2D patients are usually treated with 5-8 distinct drugs for controlling their hyperglycemia, plasma lipids, hypertension and obesity. In spite of the exhaustive efforts invested in treating MetS/T2D patients, the overall success in reaching the combined glycemic, lipemic, hypertension and body weight targets of MetS/T2D is less than 20%.

MEDICA analogs consist of highly stable, low molecular weight, new chemical entity (NCE) compounds for oral use, designed to offer an innovative and comprehensive all-in-one treatment for MetS/T2D and their component diseases.

סגל וסטודנטים מוזמנים להשתתף

לתיאום פגישה: yaelf@savion.huji.ac.il